Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
Epidemiological Burden of and Risk Factors for Ganciclovir Resistant/Refractory Cytomegalovirus in Solid Organ Transplant and Hematopoietic Stem Cell Transplant Patients: Multicentre Cohort Study
IRCCS Azienda Ospedaliero-Universitaria di Bologna
100 participants
Jun 19, 2023
OBSERVATIONAL
Conditions
Summary
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ transplant (SOT) or hematopoietic stem cell transplant (HSCT). Aims of the study are to investigate the incidence of and risk factors for GCV-RR CMV infection in SOT recipients and HSCT patients in order to design further studies aimed at preventing and improving the patient management of GCV-RR CMV infections.
Eligibility
Inclusion Criteria2
- All adult (≥ 18 years) patients who underwent SOT or HSCT developing CMV-infection treated with GC/VGC
- Ability to understand the purpose of the study and provide signed and dated informed consent
Exclusion Criteria4
- Lack of clinical and/or laboratory data regarding the type of CMV event
- Lack of the serological mismatch at transplantation
- Lack of the type of SOT or HSCT
- Lack of the patient and graft outcome at 30, 60 or 90 days after CMV event diagnosis
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(23)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05234723